|

BI 764532 - parenteral 2 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Obrixtamig

Pipeline

Phase 1: 1

Top Sponsors

  • Boehringer Ingelheim1

Indications

  • Patients With Small Cell Lung Carcinoma and Other Neoplasms1
  • Lung Cancer1
  • Cancer1

Atlanta, Georgia1 trial

A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3

Winship Cancer Institute

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.